NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments

Hall, Caroline J; Doss, Sally; Hay, Nicola; Sutcliffe, Frances; Stevens, Andrew

doi:10.1016/s1470-2045(16)00061-9

Cited by 4 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Panobinostat is a histone deacetylase inhibitor that is used in the treatment of multiple myelomas (32). Studies have reported that Panobinostat has a good antitumor effect in breast cancer (33).…”

Section: Discussionmentioning

confidence: 99%

Upregulation of LINC00511 expression by DNA hypomethylation promotes the progression of breast cancer

Liu

et al. 2021

Gland Surg

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Upregulation of LINC00511 expression by DNA hypomethylation promotes the progression of breast cancer

Liu

et al. 2021

Gland Surg

View full text Add to dashboard Cite

“…is a first-in-class potent pan-deacetylase (DAC) inhibitor [36] that has been approved in February 2015 by the US FDA (US Food and Drug Administration) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma, in patients who have received at least two prior regimens, including bortezomib and an immunomodulatory agent [37,38]. e EMA (European Medicines Agency) has also granted approval in August 2015 for this agent [39], which is also recommended by the NICE (National Institute for Health and Care Excellence) [40] for the same indication.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Panobinostat for the Treatment of Multiple Myeloma

Eleutherakis‐Papaiakovou

Kanellias

Kastritis

et al. 2020

Journal of Oncology

View full text Add to dashboard Cite

Panobinostat represents a potent oral nonselective pan-histone deacetylase inhibitor (HDAC) with activity in myeloma patients. It has been approved by the FDA and EMA in combination with bortezomib and dexamethasone for the treatment of multiple myeloma, in patients who have received at least two prior regimens, including bortezomib and an immunomodulatory agent. In order to further explore its clinical potential, it is evaluated in different combinations in relapsed/refractory and newly diagnosed multiple myeloma. This review focuses on available data about panobinostat’s pharmacology and its role in clinical practice. This review will reveal panobinostat’s efficacy as antimyeloma treatment, describing drug evolution from preclinical experimental administration to administration in phase III trials, which established its role in current clinical practice. Based on the latest data, we will present its mechanism of action, its efficacy, and most important issues regarding its toxicity profile. We will further try to shed light on its role in current and future therapeutic landscape of myeloma patients. Panobinostat retains its role in therapy of multiple myeloma because of its manageable toxicity profile and its efficacy, mainly in heavily pretreated multiple myeloma patients. These characteristics make it valuable also for novel regimens in combination with second-generation proteasome inhibitors, IMiDs, and monoclonal antibodies. Results of ongoing trials are expected to shed light on drug introduction in different therapeutic combinations or even at an earlier level of disease course.

show abstract

Panobinostat in multiple myeloma

Gertz

2016

The Lancet Haematology

View full text Add to dashboard Cite

NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments

Cited by 4 publications

References 2 publications

Upregulation of LINC00511 expression by DNA hypomethylation promotes the progression of breast cancer

Upregulation of LINC00511 expression by DNA hypomethylation promotes the progression of breast cancer

Efficacy of Panobinostat for the Treatment of Multiple Myeloma

Panobinostat in multiple myeloma

Contact Info

Product

Resources

About